Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This article gonna dive deep into Eric Faw ...

Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...

Intellia Therapeutics plunged 29% on safety concerns but rebounded as the full story emerged, showing the value of patience. Read why NTLA stock is a buy.

Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed ...

Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...

We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...

Intellia develops drugs with CRISPR-based therapies, pioneering in vivo therapies ... NTLA is a likely beneficiary of Eli Lilly's(NYSE: LLY) acquisition of Verve Therapeutics(NASDAQ: VERV), a ...